EMA backs Merck's Keytruda as first-line treatment in colorectal cancer

 

• The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Merck's (NYSE:MRK) Keytruda, an anti-PD-1 therapy, as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
• The European Commission is expected to make a final decision on the marketing authorization in Q1 2021. 
• MSI is defined by the National Cancer Institute as a change that occurs in the DNA of certain cells, such as tumor cells, in which the number of repeats of microsatellites is different from the DNA when it was inherited.
• https://seekingalpha.com/news/3643641-ema-backs-mercks-keytruda-first-line-treatment-in-colorectal-cancer